AI-generated summary
This review examines the published literature on photobiomodulation, also called low-level light therapy, as a treatment for meibomian gland dysfunction and dry eye disease. The authors aim to assess its efficacy and safety and what is known about how it works. The abstract does not state the findings of the reviewed studies, so the review's conclusions cannot be reported from this text.
- Who or what was studied
- Patients with dry eye disease or meibomian gland dysfunction
- Limits stated in the abstract
- The abstract does not report how many studies were included or what they found, so the strength of the evidence is unclear.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on tandfonline.com.
Record from PubMed, a service of the National Library of Medicine.
How to read a single study: what to check before relying on this kind of research.
Terms in this paper: Dry eye, Photobiomodulation, Inflammation. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.